Identification of novel human high-density lipoprotein receptor up-regulators using a cell-based high-throughput screening assay

被引:16
作者
Yang, Yuan
Zhang, Zhongbing
Jiang, Wei
Gao, Lei
Zhao, Guiyu
Zheng, Zhihui
Wang, Min
Si, Shuyi [1 ]
Hong, Bin
机构
[1] China Pharmaceut Univ, Sch Life Sci & Technol, Nanjing, Peoples R China
[2] Chinese Acad Sci, Inst Med Biotechnol, Beijing, Peoples R China
[3] Peking Union Med Coll, Beijing, Peoples R China
关键词
CLA-1/SR-BI; up-regulator; high-throughput screening; microbial secondary metabolites; atherosclerosis;
D O I
10.1177/1087057106297568
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Scavenger receptor class B type I (SR-BI) is the high-affinity high-density lipoprotein (HDL) receptor, and CLA-1 is the human homologue of the murine SR-B1. CLA-1/SR-BI receptor has been suggested as a new preventative and/or therapeutic target for atherosclerosis due to its pivotal role in overall HDL cholesterol (HDL-C) metabolism and its antiatherogenic activity in vivo. To search for active compounds that can increase CLA-1 transcription, a novel cell-based assay was developed for application in high-throughput screening (HTS). Human hepatoma FlepG2 cells were transfected with a CLA-1-proinoter-luciferase reporter gene construct, and the stable transfected cell line was selected and named CLAp-LUC HepG2. With rosiglitazone as a positive control, this stable cell line was used to establish a specific CLA-1 gene expression assay in a 96-well microplate format. The evaluating parameter Z' value of 0.64 showed that this cell-based HTS assay was robust and reliable. Screening of 6000 microbial secondary metabolite crude extracts identified 8 positive strains. Between 2 identified CLA-1 up-regulators produced by actinomycete strain 04-4776, 4776B may stimulate not only the expression of CLA-1 on the transcriptional and translational levels but also the activity of CLA-1 to uptake the HDL-C in HepG2 cells. The active compounds originated from this HTS assay may be developed to drug candidates or lead compounds for new anti atherosclerosis agents.
引用
收藏
页码:211 / 219
页数:9
相关论文
共 32 条
[1]  
Acton S, 1996, SCIENCE, V271, P517
[2]   The HDL receptor SR-BI: a new therapeutic target for atherosclerosis? [J].
Acton, SL ;
Kozarsky, KF ;
Rigotti, A .
MOLECULAR MEDICINE TODAY, 1999, 5 (12) :518-524
[3]   Bioactive microbial metabolites -: A personal view [J].
Bérdy, J .
JOURNAL OF ANTIBIOTICS, 2005, 58 (01) :1-26
[4]  
CALVO D, 1993, J BIOL CHEM, V268, P18929
[5]   Structure and localization of the human gene encoding SR-BI/CLA-1 - Evidence for transcriptional control by steroidogenic factor 1 [J].
Cao, GP ;
Garcia, CK ;
Wyne, KL ;
Schultz, RA ;
Parker, KL ;
Hobbs, HH .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (52) :33068-33076
[6]   Critical review of health effects of soyabean phyto-oestrogens in post-menopausal women [J].
Cassidy, A ;
Albertazzi, P ;
Nielsen, IL ;
Hall, W ;
Williamson, G ;
Tetens, I ;
Atkins, S ;
Cross, H ;
Manios, Y ;
Wolk, A ;
Steiner, C ;
Branca, F .
PROCEEDINGS OF THE NUTRITION SOCIETY, 2006, 65 (01) :76-92
[7]  
Cassidy Aedin, 2006, J Br Menopause Soc, V12, P49, DOI 10.1258/136218006777525776
[8]  
Han Chang-Hoon, 2002, J Vet Sci, V3, P265
[9]   Association between a novel 11-base pair deletion mutation in the promoter region of the scavenger receptor class B type I gene and plasma HDL cholesterol levels in Taiwanese Chinese [J].
Hsu, LA ;
Ko, YL ;
Wu, S ;
Teng, MS ;
Peng, TY ;
Chen, CF ;
Chen, CF ;
Lee, YS .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2003, 23 (10) :1869-1874
[10]   Dual effects on HDL metabolism by cholesteryl ester transfer protein inhibition in HepG2 cells [J].
Huang, ZP ;
Inazu, A ;
Kawashiri, M ;
Nohara, A ;
Higashikata, T ;
Mabuchi, H .
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2003, 284 (06) :E1210-E1219